| 摘要 |
A dye-drug conjugate for preventing, treating, or imaging cancer having the formular: (I) [Formula (I)] wherein R1 and R2 are independently selected from the group consisting of -H, alkyl, alkyl- sulphonate, alkylcarboxylic, alkylamino, aryl,-SO3H, -PO3H, -OH, -NH2, and - halogen; wherein Υ1 and Y2 is independently selected from the group consisting of alkyl, aryl, aralkyl, alkylsulphonate, alkylcarboxylic, alkylamino, ω-alkylaminium, ω-alkynyl, PEGyl, PEGylcarboxylate, ω-PEGylaminium, ω-acyl-NH, ω- acyl-lysinyl-, ω -acyl-triazole, ω- PEGylcarboxyl-ΝΗ-, ω-PEGylcarboxyl-lysinyl, and ω- PEGylcarboxyl-triazole; wherein X is selected from the group consisting of a hydrogen, halogen, CN, Me, NH2, SH and OH; and R3 and R4 are independently a hydrogen, a therapeutic agent, or an imaging moiety, wherein the therapeutic agent is selected from the group consisting of a platinum-based therapeutic agent, a small molecule therapeutic agent, a peptide, a protein, a polymer, an siRNA, a microRNA, and a nanoparticle, wherein the imaging is a radio- isotope selected from the group consisting of F18, I-125, I-124 I-123, I-131, and small molecule labeled with any of these isotopes, or wherein the imaging moiety is a chelator- complexed radioactive isotope, wherein the radioactive isotope is selected from the group consisting of Cu-64, In-1 1 1, Tc-99m, Ga-68, Lu-177, Zo-89, Th-227 and Gd-157. |
